| Strength: | |
|---|---|
| Quantity: | |
Brief Introduction:
National Medical Insurance, Category B;
Launched in 1997,
The first China-made Molgramostim in market,
National standard bulk supplier of Molgramostim,
As an important immunomodulator of tumor vaccines, Topleucon® has participated in international clinical research in Europe in recent years. The relevant research results have been published on international authoritative tumor research platforms such as American Society of Clinical Oncology (ASCO) Annual Meeting.
Indications:
1.Treatment and prevention of leukopenia caused by radiotherapy or chemotherapy,
2.Treatment of bone marrow hematopoietic dysfunction and myelodysplastic syndrome,
3.Prevention of potential infection complications caused by leukopenia,
4.Accelerating recovery of neutrophils caused by infection
For details, please refer to Instructions.
Academic progress
Research Progress: Treatment of TG01/GM-CSF and adjuvant gemcitabine in patients with pancreatic cancer significantly improved survival rate, which indicates safety and efficiency
2020-03-16
Research progress: Combination of GM-CSF and radiotherapy can induce much stronger immune response
2020-03-16
Research progress: rHuGM-CSF helps to combat serious infections by improving the host immunity
2020-03-16
Research progress: Regimen CAGM shows better effect than CAG on treatment of M4/M5 leucocythemia
2020-03-16
Research progress: Long-lasting follow-up of 15 years shows good efficacy and safety of GM-CSF
2020-03-16
Animal experiment: GM-CSF effectively suppress tumor growth in mouse cell
2020-03-16
Research progress: GM-CSF can effectively prevent post-transplant fungal infections, reduce infections, reduce infection-related mortality and improve survival
2020-03-16
Research progress: Local radiotherapy plus GM-CSF can elicit abscopal response in metastatic solid tumours and improve overall survival
2020-03-16
Research progress: Combination of GM-CSF and immune checkpoint inhibitor, ipilimumab, can improve efficacy and reduce toxicity
2020-03-16
Brief Introduction:
National Medical Insurance, Category B;
Launched in 1997,
The first China-made Molgramostim in market,
National standard bulk supplier of Molgramostim,
As an important immunomodulator of tumor vaccines, Topleucon® has participated in international clinical research in Europe in recent years. The relevant research results have been published on international authoritative tumor research platforms such as American Society of Clinical Oncology (ASCO) Annual Meeting.
Indications:
1.Treatment and prevention of leukopenia caused by radiotherapy or chemotherapy,
2.Treatment of bone marrow hematopoietic dysfunction and myelodysplastic syndrome,
3.Prevention of potential infection complications caused by leukopenia,
4.Accelerating recovery of neutrophils caused by infection
For details, please refer to Instructions.
Academic progress
Research Progress: Treatment of TG01/GM-CSF and adjuvant gemcitabine in patients with pancreatic cancer significantly improved survival rate, which indicates safety and efficiency
2020-03-16
Research progress: Combination of GM-CSF and radiotherapy can induce much stronger immune response
2020-03-16
Research progress: rHuGM-CSF helps to combat serious infections by improving the host immunity
2020-03-16
Research progress: Regimen CAGM shows better effect than CAG on treatment of M4/M5 leucocythemia
2020-03-16
Research progress: Long-lasting follow-up of 15 years shows good efficacy and safety of GM-CSF
2020-03-16
Animal experiment: GM-CSF effectively suppress tumor growth in mouse cell
2020-03-16
Research progress: GM-CSF can effectively prevent post-transplant fungal infections, reduce infections, reduce infection-related mortality and improve survival
2020-03-16
Research progress: Local radiotherapy plus GM-CSF can elicit abscopal response in metastatic solid tumours and improve overall survival
2020-03-16
Research progress: Combination of GM-CSF and immune checkpoint inhibitor, ipilimumab, can improve efficacy and reduce toxicity
2020-03-16
